Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report
This case demonstrates that sintilimab plus anlotinib may be a feasible treatment regimen for osteosarcoma patients.
Authors
- Fengxia Wang (ORCID: https://orcid.org/0000-0003-3478-8863)
- Yuanlin Qi (ORCID: https://orcid.org/0000-0002-5253-9732)
- Qianqian Zhang (ORCID: https://orcid.org/0000-0002-8756-3521)
- Gaoyan Tang (ORCID: https://orcid.org/0000-0001-6994-1376)
- Hua Zhang
Institutions
- Weifang People's Hospital (CN)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/ott.s464678
- Citations
- 1
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.28